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Introduction
Congenital hyperthyroidism is a rare disease and most
cases are caused by transplacental passage of maternal 
thyrotropin receptor (TSHR) antibodies, which leads to 
transient hyperthyroidism in infants of mothers with Graves'
disease  (1). A persistent, nonautoimmune form of 
hyperthyroidism results from gain-of-function mutation in
the TSHR gene. Heterozygous germline mutations in the
affected subjects result in constitutive activation of the
cyclic AMP (cAMP) pathway, which in turn stimulates the
thyroid hormone production and thyrocyte proliferation (2). 
Gain of function mutations are, by definition, dominant,
and alteration of one allele is thus sufficient for generating
the pathologic phenotype. Activating TSHR mutations 
can occur somatically in solitary toxic adenomas or toxic
adenomas within multinodular goiters. Germline TSHR
mutations give rise to autosomal dominant nonautoimmune
hyperthyroidism or, in case of de novo mutations, to 
sporadic nonautoimmune congenital hyperthyroidism.
The clinical features of sporadic nonautoimmune
hyperthyroidism include earlier onset of thyrotoxicosis and
more severe clinical symptoms, which are difficult to control
as compared to familial cases (3). However, a severe course
in familial nonautoimmune hyperthyroidism has also  been
reported (4,5).
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hyperthyroidism include variable severity of 
hyperthyroidism and  goiter, absence of thyroid auto-
antibodies and absence of lymphocytic infiltration in the 
thyroid histology. The hyperthyroid state typically relapses
following the cessation of antithyroid drugs. In some 
cases antithyroid drug treatment fails to control the 
hyperthyroidism at long-term follow-up and thyroidectomy
or radioiodine therapy become necessary. 
De novo activating TSHR germline mutations have been
previously reported in 14 cases as the cause of sporadic
congenital nonautoimmune hyperthyroidism and these
cases have ten different TSHR germline mutations (6,7).
Almost all mutations are located in the transmembrane
domain of the TSHR protein, which is encoded by exon 10.
So far, only one mutation has been identified in the 
extracellular domain (8).
In this report, we present a Turkish boy with sporadic
congenital hyperthyroidism who presented with severe
symptoms of hyperthyroidism in early infancy and a 
heterozygous TSHR germline mutation. Until now, 
this mutation has not been reported in sporadic cases of
nonautoimmune congenital hyperthyroidism.
Case Report
Our patient was a male infant delivered at the 39th week
of an unremarkable gestation as the first child of unrelated
Turkish parents. Birth weight was 3500 g. The parents
reported that during the neonatal period, the infant had 
suffered from poor weight gain, diarrhea, excessive sweating,
and irritability. At the age of 6 months he was referred to
our hospital. At this time, his weight was 5400 g (3-10th
percentile), total weight gain from birth was 1900 g, length
was 65 cm (25-50th percentile) and head 
circumferences 42 cm (10 -25th percentile). Blood pressure
was measured as 95/55 mmHg with a heart rate of
138beats/min. He had goiter and exophthalmos. Bone age
was significantly advanced and corresponded to three years
of age. Laboratory tests confirmed hyperthyroidism with a
TSH level of 0.05 μIU/mL (0.4-4), free T4 >6 ng /dL (0.8-1.9),
free T3 of 12.9 pg /mL (1.6-4.7), total T4 >24 μg/dL 
(4.5-12.5), total T3 of 4.1 ng /mL (0.7-1.9). TSHR, thyroid
peroxidase (TPO) and human thyroglobulin (TG) antibodies
were negative in the patient and his mother. Thyroid 
ultrasound showed diffuse enlargement of the thyroid
gland.
The patient was started on propylthiouracil and propranolol.
After four weeks of propylthiouracil treatment a euthyroid
state was reached. Thyroid hormone levels continued to 
be normal during a six-month period of follow-up with
antithyroid therapy.  When the treatment was stopped by
the family at the age of 12 months, the hyperthyroid state
relapsed with markedly elevated total and free thyroid 
hormone and suppressed TSH levels. Propylthiouracil 
treatment was reinitiated. 
Methodology and Results of the Genetic Analysis 
EDTA-blood was drawn from the index patient and his
parents for extraction of genomic DNA from peripheral
blood leucocytes using spin column method. All the exons
of the gene were sequenced by the primers placed to the
neighboring introns. Genetic analysis of genomic DNA
extracted from the patient’s peripheral blood sample
showed a heterozygous point mutation at codon 623 in
169
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Table 1. The clinical and laboratory findings of the patient at admission and at follow-up
Admission 1st month of treatment 6th month of treatment 7th month of treatment 18th month of treatment
Age (months) 6  7  12  13 24 
Weight (kg) (SDS) 5.4  (-2.8) - 8.8 (-1.1) 9.1 (-0.8) 12 (-0.4)
Height (cm) (SDS) 65 (-1.1) - 77 (+0.06) 78.5 (+0.55) 86 (-0.62)
fT3 pg/ml (1.6-4.7) 12.9 7.7 3.09 23.74 6.6
fT4 ng/dl (0.8-1.9) >6 1.28 0.59 6.8 0.6
T3 ng/ml (0.7-1.9) 4.1 3.74 1.58 4.7 3.3
T4 μg/dl (4.5-12.5) >24 11.8 5.1 >26 5.16
TSH μlU/ml (0.4-4) <0.05 0.02 0.01 <0.01 0.78
Treatment Propranolol and STOP Propranolol and Propranolol and
Propylthiouracil Propylthiouracil Propylthiouracil
T3: triiodothyronine
T4: thyroxine
fT3: free T3
fT4: free T4
TSH: thyrotropin170
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rexon 10 that codes the transmembrane domain of the
TSHR. This mutation results in an amino acid substitution of
alanine to valine. The mutation was not detected in the
peripheral blood samples of the parents.
Thus, the molecular analysis of the patient's TSHR gene
revealed a de novo heterozygous mutation (A623V) at
codon 623 in exon 10, at codon 623, which leads to an amino
acid substitution from alanine to valine at that position. The
mutation was not detected in his mother or father.
During 18 months of follow-up, the patient remained
euthyroid on propylthiouracil treatment. Table 1 shows 
clinical and laboratory findings of the patient at admission
and at follow-up. 
Discussion
Here we report a case of sporadic congenital 
nonautoimmune hyperthyroidism with an activating TSHR
germline mutation in a Turkish boy. The mutation occurred
de novo, since neither parent harbored the TSHR mutation.
In addition, both parents had normal test results of thyroid
function. The possibility of gonadal mosaicism was 
discussed with the parents to inform them about the low
recurrence risk in further pregnancies. 
This mutation has been described previously as a 
somatic mutation in toxic nodules in familial nonautoimmune
hyperthyroidism (4,9), but the germline heterozygous 
mutation (A623V) at codon 623 in exon 10 found in our
patient, has not been reported in sporadic cases. 
The first patient with sporadic nonautoimmune
congenital hyperthyroidism due to a germline mutation was
described by Kopp et al in 1995 (10). To date, fourteen
cases with sporadic activating TSHR germline mutations
have been described associated with 10 different 
mutations. Table 2 summarizes the data of 14 previously
reported cases of nonautoimmune hyperthyroidism
resulting from sporadic TSHR germline mutations, 
highlighting the variability of the clinical consequences of
this condition. 
Although there are reports of patients with relatively
severe courses also in cases of familial nonautoimmune
hyperthyroidism (4,5), inherited TSHR mutations usually
present later in life with rather mild clinical manifestation.
Sporadic TSHR mutations were found to cause severe 
thyrotoxicosis and goiter with onset in the neonatal period
or infancy. Almost all reported cases became symptomatic
within the first year of life, like our patient (11).  In sporadic
congenital nonautoimmune hyperthyroidism, patients 
with the same TSHR germline mutations display variable
phenotypes, particularly with respect to the onset of 
thyrotoxicosis. 
Our patient has clinical features similar to other cases of
sporadic nonautoimmune congenital hyperthyroidism
described in the literature. Severe neonatal hyperthyroidism
and advanced bone age characterized the phenotype of our
patient. Recurrence of thyrotoxicosis occurred when
antithyroid drug therapy was stopped. 
Our patient was born at term, while more than half 
of the previous patients were born preterm. The most
prominent features of the previously reported cases were
preterm birth and associated symptoms like developmental
delay, irritability, diarrhea and excessive sweating. 
Our patient, although born at term with a normal birth
weight, had poor weight gain, diarrhea, excessive 
sweating, and irritability. 
The size of the thyroid gland is also variable in patients
with sporadic nonautoimmune hyperthyroidism. In some
patients, the initial manifestation of the constitutively active
TSHR mutation is hyperthyroidism without any increase in
the gland mass (4,6,8,11,12,13,14,15), whereas in others
(7,10,16,17,18,19), goiter development may precede the
onset of the clinical findings of hyperthyroidism. Our patient
had grade II goiter at the time of diagnosis at age six
months. Only two cases have been reported with a nodular
goiter. These patients were 7 and 8.7 years old (10,12).
Craniosynostosis is another prominent feature, which has
been observed in seven of fourteen previously reported
cases. This feature was not present in our patient. 
Symptoms of developmental impairment such as 
mental retardation, hydrocephalus and speech disturbance
have been reported in 7 cases of sporadic nonautoimmune
hyperthyroidism (4,10,11,12,13,17,18). Our patient’s 
development was compatible with his age. This finding
could be due to a relatively early diagnosis and aggressive
therapy with antithyroid drugs. 
Accelerated bone age, a common finding in these
cases, was also evident in our patient.
In addition, various clinical findings such as jaundice,
hepatosplenomegaly, thrombocytopenia (19) and severe
respiratory symptoms such as apnea, asphyxia (6,12,15,19)
have been reported in association with this condition. 
Many of the cases were reported soon after 
their diagnosis. Longer follow-up findings have been 
reported in 8 patients aged between 6 and 22 years
(7,8,10,11,12,13,15,18).
Different therapeutic protocols had been used in 
the patients reported in the literature, even in those with
similar mutations. Total thyroidectomy had been performed
in three patients described by Gruters et al (8), Schwab et
al  (4), and Esapa et al (16). The patients described 
by Holzapfel et al (13) and Bircan et al (7) underwent a near-
total thyroidectomy after a long-term antithyroid 
treatment. The subjects described by Lavard et al (12) and
by Kopp et al (10) had received I131 therapy in addition to
subtotal thyroidectomy. The patient described by Nishihara
et al. (11) had received both medical and I131 therapy. 
In other cases (6,15,17,19),  only medical therapy had been
given. Propylthiouracil is a drug, which carries the risk of
causing severe hepatic insufficiency and it is not a 
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currently recommended as the first line of antithyroid drug 
treatment. Total thyroidectomy is planned in our patient. 
An association between genotype and phenotype in
presence of constitutively active TSHR mutations is difficult
to establish since one and the same mutation may lead 
to variability in the clinical course and onset of 
hyperthyroidism (13,14). 
Although congenital nonautoimmune hyperthyroidism is
rare, in patients with neonatal hyperthyroidism with 
negative antibodies, TSHR mutations should be included in
the differential diagnosis. Diagnosing nonautoimmune
hyperthyroidism due to activating TSHR mutation is of great
importance for both patient management and genetic 
counseling.
The early identification of individuals with 
nonautoimmune hyperthyroidism is important, because
delayed or inadequate treatment of hyperthyroidism
might lead to irreversible consequences such as mental
retardation. Thus, aggressive therapy that may include 
surgery and ablation by radiotherapy should be 
applied promptly. 
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